EXT1 Antibody, FITC conjugated

說明書

中文名稱：

EXT1兔多克隆抗體, FITC偶聯(lián)
貨號：

CSB-PA620959LC01HU
規(guī)格：

￥880
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) EXT1 Polyclonal antibody
Uniprot No.：

Q16394
基因名：

EXT1
別名：

4-alpha-N-acetylglucosaminyltransferase antibody; exostoses (multiple) 1 antibody; Exostosin 1 antibody; Exostosin glycosyltransferase 1 antibody; Exostosin-1 antibody; EXT antibody; EXT1 antibody; EXT1_HUMAN antibody; Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase antibody; glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan antibody; Langer-Giedion syndrome chromosome region antibody; LGCR antibody; LGS antibody; Multiple exostoses protein 1 antibody; Multiple exostoses protein 1 homolog antibody; N-acetylglucosaminyl-proteoglycan 4-beta-glucuronosyltransferase antibody; Putative tumor suppressor protein EXT1 antibody; TRPS2 antibody; TTV antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Recombinant Human Exostosin-1 protein (28-171AA)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

FITC
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產(chǎn)品提供形式：

Liquid
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan.
基因功能參考文獻(xiàn)：
1. The present study identified pathogenic mutations in 93% (68/73) of unrelated hereditary multiple osteochondromasprobands from 73 pedigrees. Mutations in EXT1 and EXT2 were identified in 53% (39/73) and 40% (29/73) of families. PMID: 30334991
2. Exons and flanking regions of the EXT1 and EXT2 genes were analyzed from the genomic DNA of 153 patients in 114 families with multiple osteochondromas. We identified 33 variants in EXT1 (13 frameshift, 11 nonsense, 5 missense, 2 splice site mutation, and 2 large deletions) in and 17 (6 frameshift, 6 splice site mutation, 3 nonsense, 1 missense, and 1 large deletion) in EXT2 gene. Of all 50 variants, 31 (62%) were novel. PMID: 29529714
3. RT-PCR analysis showed that the overall transcriptional activity of the main Heparan Sulfate biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma. PMID: 29104277
4. The nine mutations identified by targeted next-generation sequencing include two missense mutations (EXT1: c.1088G>A and c.2120C>T), one splicing mutation (EXT2: c.744-1G>T) PMID: 28690282
5. A novel heterozygous frameshift mutation was found in exon 4 of the exostosin-1 (EXT1) gene in the proband and the other 6 hereditary multiple exostosis (HME) affected individuals. PMID: 29419870
6. EXT1, a gene not previously linked to acute lymphoblastic leukemia via mutations, is a common interactor of NOTCH1 and FBXW7 regulating the NOTCH pathway in an FBXW7-dependend manner. PMID: 27229929
7. A novel heterozygous point mutation (c.1164+1G to A) at the 5'splice sites of intron 3 of the EXT1 gene is associated with multiple osteochondroma. PMID: 28604967
8. EXT1 is up regulated in patients after chronic rhinosinusitis, developing osteitis. PMID: 27888647
9. Owing to the appearance of c.335_336insA in exon 1 of exotosin 1, a premature stop codon was introduced, resulting in truncated exotosin 1. As a result integrated and functional exotosin 1 was reduced. PMID: 28035357
10. We report the discovery of a non-sense mutation in EXT2 in an 11-y-old boy diagnosed with multiple osteochondroma. PMID: 25591329
11. We found that the prevalence of EXT1 mutations was greater than that of EXT2 mutations in Japanese multiple osteochondromas families. PMID: 26961984
12. Ext1 heterozygosity causes a modest effect on postprandial lipid clearance in humans PMID: 25568062
13. EXT1 mutation is associated with multiple osteochondromatosis. PMID: 25230886
14. Heterozygous loss of function of EXT1 and EXT2 results in a decreased arteriolar endothelial glycocalyx but improved flow mediated vasodilation. PMID: 25468659
15. there is a putative genetic connection between TCF7L2 and EXT in the context of Hereditary Multiple Exostoses PMID: 25498973
16. loss of function of EXT1 subjects with hereditary multiple exostoses affects pancreatic insulin secretion capacity and development. PMID: 25541963
17. Results provide a new frameshift mutation in EXT1, further emphasizing the dysfunction of the EXT gene family as a cause of hereditary multiple exostosis. PMID: 25421355
18. exostosin 1 (EXT1), which is involved in biosynthesis of heparan sulfate, plays a role in filovirus entry PMID: 25741008
19. EXT1 and EXT2 heterozygous mutations in 18 (54.6 %) and ten (30.3 %) probands respectively, which represents a total of 28 (84.9 %) index cases. PMID: 24532482
20. a novel disease-causing EXT1 mutation in a pedigree with Hereditary multiple exostoses PMID: 24297320
21. splicing mutation, IVS5+1G>A, of EXT1, first identified in Chinese population, may be responsible for HME in the studied pedigree. EXT1 and EXT2 mutation rates may be different between the Chinese and Western populations PMID: 24568913
22. Exome sequencing and functional analysis identifies a novel mutation in EXT1 gene that causes multiple osteochondromas. PMID: 24009674
23. these findings are useful for extending the mutational spectrum in EXT1 and EXT2 and understanding the genetic basis of multiple osteochondromas in Chinese patients. PMID: 24120389
24. Novel and recurrent mutations occur in the EXT1 and EXT2 genes in Chinese kindreds with multiple osteochondromas. PMID: 23629877
25. we found a mutation in EXT1 or in EXT2 in 95% of the Spanish patients. Eighteen of the mutations were novel. PMID: 23439489
26. Results indicate that intronic deletion and duplication of EXT1 as a causative mechanism for multiple osteochondromas (MO) not detected by conventional diagnostic methods. PMID: 23341036
27. No mutations have been found among all exons of the EXT1 and EXT2 genes in this family. Linkage analysis is necessary for identifying the cause of this disease. PMID: 23450490
28. 20 novel EXT1/EXT2 mutations and one large EXT2 deletion identified in the largest Southern Italy cohort of patients affected by hereditary multiple exostosis. PMID: 23262345
29. analysis of novel pathogenic mutations in EXT1 and EXT2 that may have roles in multiple osteochondroma in Chinese patients PMID: 22820392
30. A novel nonsense mutation of EXT1 gene found in patient diagnosed with multiple hereditary exostoses. PMID: 22637216
31. Two novel EXT1 gene mutations were identified and no mutation was found in EXT2 gene in two families with multiple osteochodromas. PMID: 22040554
32. A polymorphic G/C-SNP at -1158 bp (rs34016643) was demonstrated to be located in a USF1 transcription factor binding site, which is lost with the presence of the C-allele resulting in a ~56% increase in EXT1 promoter activity. PMID: 22037484
33. Fifteen mutations and large deletions, of which nine are new, were detected in the EXT1 and EXT2 gene by sequence analysis, FISH and MLPA analysis. PMID: 21499719
34. Molecular characterization of EXT1- and EXT2-deletion breakpoints in multiple osteochondroma indicates that non-allelic homologous recombination between Alu-sequences as well as NHEJ are causal and that the majority of these deletions are nonrecurring. PMID: 21703028
35. Out of the 17 patient samples with previously undetected mutations, a low level of deletion of the EXT1 gene in about 10-15% of the blood cells was detected in two patients and mosaic deletion of the EXT2 was detected in one patient. PMID: 21280143
36. 8 novel mutations of EXT1 and EXT2 genes among families and sporadic cases with multiple exostoses were identified. PMID: 21039224
37. Loss of heterozygosity for EXT1 is associated with multiple osteochondromas. PMID: 20813973
38. This heterozygous mutation in the EXT1 gene must be classified as pathogenic and can be regarded as the cause of hereditary multiple exostosis (HME) in this Chinese family. PMID: 20578942
39. we found a splice site mutation in the EXT1 gene intron 5 (IVS5-2 A > G) resulting in the deletion of 9 bp of cDNA encoding three evolutionarily conserved amino acid residues. This child patient suffered from a severe form of exostoses. PMID: 20618940
40. results clearly indicate that, in most cases, biallelic inactivation of EXT genes does not account for osteochondromas formation; this mechanism should be regarded as a common feature for hereditary osteochondromas transformation PMID: 20418910
41. A novel EXT1 gene mutation causing hereditary multiple exostoses occurred in a Chinese family. PMID: 20025490
42. Two novel EXT1 gene mutations and two novel EXT2 gene mutations were identified in two and three hereditary multiple exostoses pedigrees, respectively. PMID: 19839753
43. deletion mutation of EXT1 is associated with autism in two patients with hereditary multiple exostoses PMID: 12032595
44. EXT1 alone and the EXT1/2 heterocomplex can act as heparan sulfate polymerases in vitro without the addition of additional auxiliary proteins PMID: 12907669
45. EXT1 function is abrogated in human cancer cells by transcriptional silencing associated with CpG island promoter hypermethylation. The epigenetic inactivation of EXT1, a glycosyltransferase, leads to the loss of heparan sulfate synthesis PMID: 15385438
46. Variations in EXT1 gene is associated with multiple osteochondromas PMID: 15586175
47. Promoter methylation was not detected in any of the chondrosarcoma cases in EXT1. PMID: 15796962
48. ANovel heterozygous acceptor splice site mutation of EXT1 results in hereditary multiple exostosis(HME) associated with low peak bone mass. Possible additional role for EXT1 in bone biology and in regulating bone density. PMID: 15985493
49. analysis of multiple osteochondroma-related mutations in EXT1 and EXT2 PMID: 16088908
50. We found three novel mutations (S277X in the EXT1 gene, and G194X and 939+1G>A in the EXT2 gene) and a known mutation (Q172X in the EXT2 gene)in hereditary multiple exostoses PMID: 16638657
顯示更多

收起更多
相關(guān)疾病：

Hereditary multiple exostoses 1 (EXT1); Tricho-rhino-phalangeal syndrome 2 (TRPS2); Chondrosarcoma (CHDSA)
亞細(xì)胞定位：

Endoplasmic reticulum membrane; Single-pass type II membrane protein. Golgi apparatus membrane; Single-pass type II membrane protein. Note=The EXT1/EXT2 complex is localized in the Golgi apparatus.
蛋白家族：

Glycosyltransferase 47 family
組織特異性：

Ubiquitous.
數(shù)據(jù)庫鏈接：

HGNC: 3512

OMIM: 133700

KEGG: hsa:2131

STRING: 9606.ENSP00000367446

UniGene: Hs.492618

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human